Hyperprolactinemia as one of frequent adverse effects associated with the use of atypical antipyschotics is oftenly neglected but can interrupt the compliance of treatment. There are clinical trials regarding improvement of hyperprolactinemia after switching to olanzapine while some trials regarding the opposite and the improvement with aripiprazole. We reviewed a case in which olanzapine induced  hyperprolactinemia-amenorrhea normalized without clinical worsening after  switching to aripiprazole.